Company intelligence / Profile preview
ViaNautis Bio
Cambridge, England, United Kingdom
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
ViaNautis Bio (formerly SomaServe) is a preclinical-stage biotechnology company developing genetic nanomedicines using its non-viral polyNaut nanovesicle platform to deliver nucleic acid and other cargos across biological barriers, with internal programs in cystic fibrosis and CNS indications and no clinical-stage assets yet reported.[1][3][4][5]
- Therapeutic areas
- NeurologyPulmonology
- Modalities
- NanoparticleNanovesiclemRNA-based drugsSmall interfering RNARNA therapyDNA vaccineGene therapySynthetic oligonucleotideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Eli Lilly and Company
Beyond the preview
Go deeper on ViaNautis Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViaNautis Bio.